Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users

References

• Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 2011;123:e18-e209
   PubMed Web of Science ®Google Scholar
• Bassand J-P, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660
   PubMed Web of Science ®Google Scholar
• Menzin J, Wygant G, Hauch O, et al. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin 2008;24:461-8
   PubMed Web of Science ®Google Scholar
• Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Managed Care 2009;15(2 Suppl):S36-41
   PubMedGoogle Scholar
• Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Managed Care Pharm: JMCP 2005;11:300-6
   PubMedGoogle Scholar
• McCollam P, Etemad L. Cost of care for new-onset acute coronary syndrome patients who undergo coronary revascularization. J Invasive Cardiol 2005;17:307-11
   PubMedGoogle Scholar
• Gurfinkel EP, Perez de la Hoz R, Brito VM, et al. Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery. Int J Cardiol 2007;119:65-72
   PubMed Web of Science ®Google Scholar
• Yang Z, Olomu A, Corser W, et al. Outpatient medication use and health outcomes in post-acute coronary syndrome patients. Am J Managed Care 2006;12:581-7
   PubMed Web of Science ®Google Scholar
• Jennings DL, Petricca JC, Yageman LA, et al. Predictors of rehospitalization after acute coronary syndromes. Am J Health-Syst Pharm: AJHP: Off J Am Soc Health-Syst Pharm 2006;63:367-72
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Lin Z, Keenan PS, et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA 2013;309:587-93
   PubMed Web of Science ®Google Scholar
• Kociol RD, Lopes RD, Clare R, et al. International variation in and factors associated with hospital readmission after myocardial infarction. JAMA 2012;307:66-74
   PubMed Web of Science ®Google Scholar
• Hess CN, Shah BR, Peng SA, et al. Association of early physician follow-up and 30-day readmission after non-ST-segment-elevation myocardial infarction among older patients. Circulation 2013;128:1206-13
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 2010;121:569-83
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction–executive summary. J Am Coll Cardiol 2007;50:e1-157
   PubMed Web of Science ®Google Scholar
• Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update). Circulation 2012;126:875-910
   PubMed Web of Science ®Google Scholar
• Fox KAA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 2004;110:1202-8
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923-32
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheter Cardiovasc Interv 2012;79:453-495
   PubMed Web of Science ®Google Scholar
• Heart K, Nauheim B, Bassand J, et al. Updated ESC guidelines for managing patients with suspected non-ST-elevation acute coronary syndromes. Eur Heart J 2011;32:2909-10
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindi RG, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:e344-426
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:529-55
   PubMed Web of Science ®Google Scholar
• Lin DY, Feuer EJ, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-34
   PubMed Web of Science ®Google Scholar
• Kass RE, Raftery AE. Bayes factors. J Am Stat Ass 1995;90:773-95
   Web of Science ®Google Scholar
• Kruschke JK. Bayesian assessment of null values via parameter estimation and model comparison. Persp Psychol 2011;6:299-312
   PubMed Web of Science ®Google Scholar
• Olson WH, Ma Y-W, Laliberté F, et al. Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel. J Clin Pharm Ther 2014;39:663-72
   PubMed Web of Science ®Google Scholar
• Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug. Circulation 2010;121:71-9
   PubMed Web of Science ®Google Scholar
• Davies A, Bakhai A, Schmitt C, et al. Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. J Med Econ 2013;16:510-21
   PubMedGoogle Scholar
• Mauskopf JA, Graham JB, Bae JP, et al. Cost-effectiveness of prasugrel in a US managed care population. J Med Econ 2012;15:166-74
   PubMedGoogle Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86
   PubMed Web of Science ®Google Scholar